Clinical Trial Update: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

This clinical trial update reports a Phase 3 study comparing tirzepatide (LY3298176) with dulaglutide for major adverse cardiovascular events in adults with typ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MOUNJARO (tirzepatide)
• TRULICITY (DULAGLUTIDE)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED